PT-Journal文章Au-justeau - Bailly，Sebastien Au - Gervès-pinquié，ChloéAu - Trzepizur，Wojciech Au - Meslier，Nicole Au - Goupil，FrançoisAu - Pigeanne，Thierry Au - Launois，Sandrine Au - Leclair-Visonneau，Laurene Au - Masson，Philippe Au - Bizieux-Thamination，Acya Au - Racineux，Jean-Louis Au - Gozal，David Au - Gagnadoux，FrédéricEd - ，Ti - 患者睡眠呼吸暂停患者的患者患者患者治疗援助 - 10.1183 / 13993003.01935-2021 DP - 2021 1月1日 - 欧洲呼吸期刊PG - 2101935 4099 - //www.qdcxjkg.com/content/early/2021/08/12/13993003.01935-2021.short 4100 -//www.qdcxjkg.com/content/early/2021/08/12/13993003.01935-2021/08/12/13993003.fulll ab - 越来越多的证据表明阻塞性睡眠呼吸暂停（OSA）有助于癌症风险;然而，有限的数据可用于连续正气道压力（CPAP）治疗对癌症发病率的影响。我们的目标是判断是否与OSA的非粘附患者相比，依赖于CPAP治疗的依赖性与所有癌症发病率的降低有关。该研究依赖于多期四学习收费的数据，与健康有关。管理数据，例如识别新发起癌症。我们包括患者为OSA规定的CPAP，在诊断睡眠研究之前没有癌症史，或在CPAP的第一年。记录的CPAP每晚至少4小时的患者被定义为粘附者。那些在晚上停产或使用CPAP的人构成了不遵守的群体。进行治疗加权分析的倾向评分逆概率，以评估CPAP依从性对癌症风险的影响。结果后[四分位数]随访5.4 [3.1-8.0]年，437（9.7％） of 4,499 patients developed cancer, 194 (10.7%) in the non-adherent group (n=1817) and 243 (9.1%) in adherent patients (n=2682). The final weighted model showed no significant impact of CPAP adherence on all-cause cancer risk (sub distribution hazard ratio [95% confidence interval]): 0.94 [0.78; 1.14]).Conclusions Adherence to CPAP therapy in OSA patients was not associated with a reduction in all-cancer incidence. Whether adherent CPAP therapy of OSA might reduce the risk of specific cancer sites should be further evaluated.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Grégoire Justeau has nothing to disclose.Conflict of interest: S. Bailly reports Consulting fees for methodology and statistical analyses from ISRS Pays de la Loire, outside the submitted work.Conflict of interest: Chloé Gervès-Pinquié has nothing to disclose.Conflict of interest: Wojciech Trzepizur has nothing to disclose.Conflict of interest: Nicole Meslier has nothing to disclose.Conflict of interest: François Goupil has nothing to disclose.Conflict of interest: Thierry Pigeanne has nothing to disclose.Conflict of interest: Sandrine Launois has nothing to disclose.Conflict of interest: Laurene Leclair-Visonneau has nothing to disclose.Conflict of interest: Philippe Masson has nothing to disclose.Conflict of interest: Acya Bizieux-Thaminy has nothing to disclose.Conflict of interest: Jean-Louis Racineux has nothing to disclose.Conflict of interest: D. Gozal reports NIH grants outside the submitted work. All other authors have nothing to disclose.Conflict of interest: F. Gagnadoux reports support for the present manuscript from Institut Recherche en Santé Respiratoire des Pays de la Loire to University Hospital of Angers; consulting fees from NYXOAH, SEFAM and RESMED; payment or honoraria for lectures from CIDELEC, ASTEN SANTE and BOEHRINGER INGELHEIM; payment for expert testimony from BOEHRINGER INGELHEIM; support for attending meetings and/or travel from ASTEN SANTE and ACTELION; participation on a Data Safety Monitoring Board or Advisory Board for JAZZ PHARMACEUTICAL; receipt of equipment, materials, drugs, medical writing, gifts or other services from INSPIRE to University Hospital of Angers, outside the present work.